BiotechTube

enzalutamide + bicalutamide

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostatic Neoplasms

Conditions

Prostatic Neoplasms

Trial Timeline

Mar 22, 2011 → Nov 8, 2017

NCT ID
NCT01288911

About enzalutamide + bicalutamide

enzalutamide + bicalutamide is a phase 2 stage product being developed by Astellas Pharma for Prostatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01288911. Target conditions include Prostatic Neoplasms.

What happened to similar drugs?

15 of 20 similar drugs in Prostatic Neoplasms were approved

Approved (15) Terminated (0) Active (5)
✅Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
✅Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
✅Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved
✅Tamsulosin OCAS + PlaceboAstellas PharmaApproved
✅TadalafilEli LillyApproved
✅ErtapenemMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01664923Phase 2Completed
NCT01288911Phase 2Completed

Competing Products

20 competing products in Prostatic Neoplasms

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
40
Placebo + tadalafilEli LillyPhase 3
40
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
29
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
43
tadalafil + placeboEli LillyPhase 2
35
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue MedicationDaiichi SankyoPhase 1/2
39
Enzalutamide + Abiraterone acetateAstellas PharmaPre-clinical
26
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
Novel hormonal therapyAstellas PharmaPre-clinical
26
ASP3550Astellas PharmaPhase 2
35
Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
43
Novel hormonal therapyAstellas PharmaPre-clinical
26
tamsulosin 0.4mgAstellas PharmaPre-clinical
22
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
43
Enzalutamide + NSAA + LHRHA or Surgical CastrationAstellas PharmaPhase 3
44
Tamsulosin OCASAstellas PharmaApproved
43
degarelixAstellas PharmaPhase 2
35
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
43
Tadalafil + PlaceboEli LillyPhase 2
35
TadalafilEli LillyApproved
43